Navigation Links
Common diabetes drug may halt growth of cysts in polycystic kidney disease

INDIANAPOLIS Researchers report that a drug commonly used to treat diabetes may also retard the growth of fluid-filled cysts of the most common genetic disorder, polycystic kidney disease. PKD does not discriminate by gender or race and affects one in 1,000 adults worldwide.

Researchers from the schools of Science and Medicine at Indiana University-Purdue University Indianapolis and colleagues from the Mayo Clinic report this month in the online peer-reviewed journal PPAR Research that pioglitazone appears to control the growth of PKD cysts.

Using a rat model that has the same genetic mutation as a form of human PKD, the two research groups independently tested a pioglitazone treatment regimen and found that it slowed down both kidney and liver cyst growth by inhibiting a chloride channel in the cells of these organs.

Normally pioglitazone works by making the body more sensitive to its own insulin. However, in studying why this class of drugs causes fluid retention, Bonnie L. Blazer-Yost, Ph.D., professor of biology at the IUPUI School of Science and corresponding author of the new study, serendipitously found that it also inhibits a chloride channel.

"We thought that since this class of drugs inhibits the body's chloride channels, then it would be a good candidate to treat PKD, a disease in which excessive chloride and water are transported into the cysts of the kidneys and the liver causing them to expand," said Blazer-Yost, Ph.D.

A normal kidney is the size of a fist. A polycystic kidney is the size of a football. Currently there is no cure for PKD and therapy options are limited. Organ transplantation is the most common treatment.

"The idea of using a chloride channel inhibitor to treat PKD is not new. What is new is our finding that an insulin sensitizing agent like piogltiazone inhibits chloride channels. The finding that pioglitazone, which has already been approved by the Food and Drug Administration for diabetes, can halt cyst progression and may be an effective and well-tolerated treatment for this chronic disease, is exciting. Confirmation of these results in other animal models of PKD would be a useful next step.

"We know from long-term experience that this drug has a good safety profile. Strategies that minimize adverse events are important when considering treatments for a chronic disease such as PKD," said Blazer-Yost, a physiologist who hopes that human trials of pioglitazone therapy for PKD can be conducted in the near future.


Contact: Cindy Fox Aisen
Indiana University School of Medicine

Related biology news :

1. New book examines health and environmental impacts of common (and not-so-common) chemicals
2. Scientists describe new approach for identifying genetic markers for common diseases
3. Researchers find first genetic evidence for loss of teeth in the common ancestor of baleen whales
4. First genetic link to common migraine exposed
5. Low bone mineral density common in children and teenagers with inflammatory bowel disease
6. Scientists find new twist on drug screening to treat common childhood cancer
7. Common orchid gives scientists hope in face of climate change
8. Pancreatic cancers use fructose, common in the Western diet, to fuel their growth
9. Rare and common genetic variations responsible for high triglyceride levels in blood
10. Heat waves could be commonplace in the US by 2039, Stanford study finds
11. New rust resistance genes added to common beans
Post Your Comments:
Related Image:
Common diabetes drug may halt growth of cysts in polycystic kidney disease
(Date:8/23/2017)... general public,s help is being enlisted in what,s thought to be the ... the human body –and are believed to affect health.  ... The Microbiome Immunity Project is the largest study to ... The project's goal is to help advance scientific knowledge of the role ... The ...
(Date:6/14/2017)... -- IBM (NYSE: IBM ) is introducing several innovative partner ... developing collaboration between startups and global businesses, taking place in ... event, nine startups will showcase the solutions they have built ... France is one of ... 30 percent increase in the number of startups created between ...
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... a United States multicenter, prospective clinical study that demonstrates the accuracy of ... capable of identifying clinically significant acute bacterial and viral respiratory tract infections ...
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for ... complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a ...
(Date:10/11/2017)... ... 2017 , ... Personal eye wash is a basic first aid supply for any work environment, ... eye do you rinse first if a dangerous substance enters both eyes? It’s one less ... with its unique dual eye piece. , “Whether its dirt and debris, or an acid ...
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
Breaking Biology Technology: